Daily digest

What's trending, October 4, 2026

In the news

Tirzepatide cuts fat mass by 35% while preserving skeletal muscle

News-Medical reports on a retrospective, real-world study of 122 adults with overweight or obesity, without type 2 diabetes, treated at two centers in Palermo, Italy. Alongside diet and activity advice, 24 weeks of tirzepatide was associated with fat mass falling 35.4% while skeletal muscle mass stayed stable. There was no control arm, and most participants were women.

Why it matters: Relevant to Maryland adults weighing medical weight loss, and to clinicians who refer them, interested in body-composition data from real-world tirzepatide care.

news-medical.net · October 4, 2026

Our summary →

In the news

Women are turning to testosterone, but what does the science actually say?

Medical Xpress republishes a Conversation explainer by Daniel Kelly on women's growing use of testosterone. A 2019 meta-analysis of 36 randomized trials supports it for distressing low sexual desire after menopause, the only evidence-backed use. An observational UK study of 510 women reported mood and cognitive improvements but cannot show causation. Long-term safety data remain limited, and the US has no approved female product.

Why it matters: Relevant to postmenopausal women in Maryland weighing menopause care options and to the gynecologists and primary care clinicians who discuss hormone therapy with them.

medicalxpress.com · October 4, 2026

Our summary →

AthleticsMD Clinical Desk

Today's front page

The newest articles and the day's news on GLP-1 & weight loss, Metabolic health, Hormones and more.

Go to the front page →

AthleticsMD

Schedule an evaluation

AthleticsMD in Columbia and Laurel/Fort Meade builds prehabilitation, rehabilitation and physician-guided weight-loss plans around your own history.

Schedule an evaluation →